

# 1 Treatment of cutaneous leishmaniasis with sodium stibogluconate 2 and allopurinol in a routine setting in Ethiopia: clinical and patient- 3 reported outcomes and operational challenges

4  
5 Saskia van Henten<sup>1</sup>, Fentaw Bialfew<sup>2</sup>, Seid Hassen<sup>2</sup>, Feleke Tilahun<sup>2</sup>, Johan van Griensven<sup>1</sup>,  
6 Seid Getahun Abdela<sup>3</sup>

7 <sup>1</sup>Institute of Tropical Medicine, Antwerp, Belgium

8 <sup>2</sup>Boru Meda Hospital, Dessie, Ethiopia

9 <sup>3</sup>Wollo University, Dessie, Ethiopia

10

## 11 Abstract

12 Cutaneous leishmaniasis (CL) is common in Ethiopia, but the national guideline does not offer  
13 specific treatment recommendations. Consequently, different treatment regimens are used  
14 in the country, without quality evidence. In Boru Meda Hospital, sodium stibogluconate (SSG)  
15 is routinely used combined with allopurinol for systemic CL treatment, although evidence on  
16 effectiveness is limited.

17 An observational cohort study was done to document clinical treatment outcomes in patients  
18 receiving SSG/allopurinol at the end of each 28-day treatment cycle and after 180 days.  
19 Patient-reported outcomes were assessed by asking patients to rate lesion severity and by  
20 the dermatological life quality index.

21 A total of 104 patients were included. After one treatment cycle only four patients were  
22 clinically cured, although patient-reported outcomes significantly improved. The majority (88)

23 of patients were appointed for a second treatment cycle, of which only 37 (42%) came. Among

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 36 patients who came for final outcome assessment, 50% was cured. Follow-up and  
25 treatment was severely affected by conflict; drug stockouts and insufficient ward capacity for  
26 treatment were additional challenges.

27 Treatment outcomes of SSG/allopurinol were relatively poor, and most patients required  
28 more than one cycle of treatment. Shortage of drugs and beds indicates the existing gaps in  
29 providing CL treatment in Ethiopia.

30 **Keywords:** *Leishmania aethiopica*, operational research, pentavalent antimonials, treatment  
31 extension

## 32 Introduction

33 Cutaneous leishmaniasis is a common dermatological condition in Ethiopia, where  
34 approximately 20,000 – 50,000 patients are affected each year [1]. The causative species is  
35 *Leishmania aethiopica*, which typically causes severe lesions on the face that are difficult to  
36 treat [2].

37 Due to lack of good quality evidence for *L. aethiopica* treatment outcomes, the national  
38 guideline does not recommend specific treatments [3], but only mentions therapeutic options  
39 without specifying the duration. In practice, treatment extension is common [4]–[6], and  
40 different combinations of treatment regimens are practiced [4],[6],[7]. As treatment efficacy  
41 is species-dependent, there is a dire need to document outcomes of routinely used treatment  
42 options for *L. aethiopica*. Intravenous or intramuscular Sodium stibogluconate (SSG) remains  
43 the most widely used treatment in Ethiopia. In Boru Meda General Hospital, treatment with  
44 systemic SSG is routinely combined with low dose allopurinol, but outcomes have never been  
45 reported.

46 Looking beyond clinician-assessed cure rates, accounting for patient-perspectives is crucial,  
47 especially for diseases that negatively affect individuals through psychosocial impact. A recent  
48 publication [8] called for including outcomes related to quality of life in studies looking at  
49 treatment effectiveness. To date, this has rarely been done around the globe.

50 In Ethiopia, anecdotal evidence also points to operational challenges such as drug shortages,  
51 insufficient bed capacity for inpatient treatment, and poor patient follow-up. Better  
52 documentation of these challenges is needed to properly outline and address current gaps in  
53 CL treatment. Additionally, parasitological confirmation through demonstration of parasites  
54 is required according to the national guideline, while monitoring renal and hepatic function

55 as well as electrocardiography changes is mentioned to evaluate toxicity, without mention of  
56 specific frequency. However, it is unclear how often this is done routinely.

57 In this study, we wanted to document SSG/allopurinol clinical treatment outcomes,  
58 determine how often treatment extension was given, and explore how patients reported their  
59 outcomes by looking at patient-reported outcomes using the dermatological life quality  
60 index, and patient-rated lesion severity. We also described the operational challenges  
61 encountered throughout this project.

## 62 **Methods**

### 63 *Setting*

64 The research took place at Boru Meda General Hospital. This hospital which gives specialized  
65 dermatology and ophthalmology services with a high caseload of leprosy and CL patients [9].

66 There is a dermatology ward which has 40 beds. Patients who are confirmed either clinically  
67 or microscopically with a skin slit smear are treated either with local treatment by  
68 intralesional SSG or cryotherapy (if available) or with systemic treatment.

69 Routine treatment for severe CL cases that need systemic treatment consists of one or more  
70 cycles of 28 days of intramuscular 20mg/kg SSG with a maximum dose of 850mg/day in  
71 combination with one 100mg tablet of allopurinol. SSG is given intravenously in case patients  
72 cannot tolerate intramuscular injections. Patients are typically admitted for the entire course  
73 of treatment. SSG is made available through the World Health Organization via the Ministry  
74 of Health.

75

76

77 *Design, population, recruitment, and sample size*

78 This was an observational cohort study among patients with CL who received systemic SSG  
79 with allopurinol following routine clinical care decisions. Patients with a clinical or  
80 parasitological diagnosis of CL who were started on SSG with allopurinol were invited to the  
81 study consecutively. Study recruitment started on 15 February 2021, with the last patient  
82 recruited on 04 August 2022, with several interruptions due to political unrest in the area  
83 (armed conflict between the Ethiopian government and Tigray militants lasted from 3  
84 November 2020 until 3 November 2022).

85 Patients visits were planned at baseline (BL) before starting treatment , for each subsequent  
86 treatment cycle (Cycle 1 (C1), Cycle 2 (C2) etc.) with study visits planned at the end of each  
87 treatment cycle before discharge, and at day 180 (D180) since starting treatment. Patients  
88 were also instructed to come back between visits if their lesion did not respond to treatment  
89 or was worsening. All information produced during routine diagnosis and treatment was  
90 captured, including lab tests that were performed and their respective results.

91 The original sample size was planned to be 117 patients. Sample size calculation was based  
92 on proportion of cure at D180 , with a required precision of 10%, using a 95% confidence level,  
93 and a conservative estimate of 50% cure. This gave a sample size of 97 patients, which was  
94 inflated with 20% to account for loss to follow-up, leading to a final sample size of 117  
95 patients. Due to the conflict and stockouts, recruitment took much longer than planned.  
96 Therefore, recruitment was terminated prematurely after a long treatment stockout  
97 prevented inclusion of individuals beyond 104 patients.

98

99 *Lesion assessment*

100 Before treatment started, the study clinician assessed the lesion by measuring the size of the  
101 largest diameter, counting the number of active lesions, classifying the type of CL as localized  
102 CL (LCL), muco-cutaneous CL (MCL), and diffuse CL (DCL) [3], and by noting the lesion  
103 characteristics (nodular, plaque, ulcerated etc.). The largest lesion was considered as the  
104 index lesion.

105 *Patient-reported outcome measures*

106 The Amharic version of the dermatological life quality index (DLQI) and children's DLQI (cDLQI)  
107 questionnaires [10] (for age between 4- 16 years) were administered to patients by the study  
108 staff at each study visit (BL, C1, C2 (if applicable), etc., D180). The DLQI questions were not  
109 asked to patients below the age of four. For children up to eight years old, the questions were  
110 posed to the parent/guardian, while for those aged eight up to twelve years, the questions  
111 were asked both to the patient and the parent/guardian. For children above 12, only the  
112 child's answer were considered. Questionnaires were scored and analyzed as recommended  
113 [10],[11], with total scores categorized from no effect to extremely large effect and removing  
114 questionnaires with answers on eight or less questions as invalid.

115 Patient-reported outcomes were assessed by asking patients to rate the severity of their  
116 lesion on a Likert scale as clear (1), almost clear (2), mild (3), moderate (4) or severe (5) at BL,  
117 C1 and any subsequent cycles, and D180.

118 *Clinical outcome assessment*

119 Lesions were assessed by the clinician at the end of each treatment cycle and at D180.  
120 Patients were classified as cured if all lesions that were present at BL had complete

121 reepithelization (if ulcerated) and flattening. Patients were categorized as substantial  
122 improvement if not all lesions cured, but there was at least 50% improvement of all lesions  
123 compared to BL. Minor improvement required all lesions to have at least 1-49% improvement  
124 compared to BL. Worsening was classified compared to the previous lesion assessment, which  
125 could be either due to worsening of previously present lesions, or appearance of new lesions.  
126 Photographs of the lesions were taken at each study visit to capture the lesion characteristics  
127 and outcomes for cross-checking and quality control.

128 Although we initially planned to include only outcomes 120-240 days after starting treatment,  
129 due to the conflict and subsequent travel restrictions, we were more lenient and considered  
130 all outcome assessment more than 110 days after starting treatment for D180 outcome.

#### 131 *Sample collection*

132 This study planned to use the routine skin slit for PCR confirmation, and collected blood and  
133 non-invasive tape disc samples (D-Squame, MonaDerm) from each study visit for further  
134 analysis.

#### 135 *Data collection and analysis*

136 A paper data collection form was used to collect patient information which was double  
137 entered in a REDCap database [12]. Analysis was done using R version 4.1.3 [13]. To describe  
138 the population, numbers, proportions, with medians and interquartile ranges (IQRs) were  
139 used. Treatment outcomes were analyzed as categorical variable with multinomial 95%  
140 confidence intervals (95% CIs). Cure rate was also analyzed as a proportion with binomial 95%  
141 CIs. Differences in DLQI scores and patient global assessment over time were analyzed using

142 the Wilcoxon-signed-rank test. Kappa coefficients were used to measure agreement between  
143 when patient's rated their lesion as clear, and when the clinician rated the lesion as cured.

#### 144 *Patient tracing*

145 Patient tracing was done over the phone, using patient information (phone number of the  
146 patient and at least one family member/neighbor) collected at BL. Patients were called if they  
147 were late for an appointment to ask them if they wanted to come. At the end of the study, all  
148 patients who missed their D180 visit were called to ask whether they thought their lesion was  
149 cured, substantially improved, the same, or worse compared to before and they were asked  
150 why they missed their outcome visit.

## 151 **Results**

152 A total of 104 patients were included in the study (Supplementary Figure 1), described in  
153 Table 1. The majority (85, 81.7%) was referred from health centers or primary hospitals.  
154 Patients frequently (74/104, 71.1%) used traditional treatment before coming to the hospital  
155 for CL care. Many patients had also tried several modern medications such as ointments and  
156 (mostly systemic) antibiotics, but only 6 (5.8%) had previously been treated for CL at a known  
157 CL treatment center.

158 The median duration of symptoms at enrollment into the study was 11.5 months (IQR 7.0 -  
159 17.0). For three quarters (80, 76.9%) the full cost of their admission and treatment was  
160 covered by health insurance. Patients came from districts up to 200 kilometer away, although  
161 patients more frequently came from areas close to the hospital.

162

163



164 *Patient characteristics*

165 The median age was 18.0 years, with 25% (26) of patients younger than twelve years. More  
166 than half of patients (69, 66.3%) presented with mucosal involvement, whereas five (4.8%)  
167 were classified as DCL. A severe MCL patient is shown in Figure 1. Most patients had a single  
168 lesion, which was most frequently on the face.

169 **FIGURE OF PATIENT NOT SHOWN IN PREPRINT**

170 **Figure 1. A patient with severe MCL.** A) *Swollen, erythematous, and crusted plaques on the*  
171 *face which restricted opening of the eyelid. The patient rated his lesion as severe and had a*  
172 *DLQI score of 16. B) Reduced swelling and crusting with flattening and darkening of the lesions*  
173 *after treatment cycle 1, with substantial improvement as clinical outcome. DLQI score was 9*  
174 *and patient-reported severity was moderate. C) Further reduction in swelling and plaque-*  
175 *formation with substantial improvement as clinical outcome after cycle 2. DLQI score 8 and*  
176 *patient-assessment mild. D) Lesion was rated as cured with significant remaining scar tissue*  
177 *after cycle 3. Swelling around the eyes has almost completely gone. DLQI was 3 and the patient*  
178 *rated the lesion as mild. Treatment was not extended after the third cycle. E) Worsening with*  
179 *increased swelling, erythema, and papules on both cheeks at D180. The patient rated his DLQI*  
180 *as 20, and his lesion as severe.*

181

182 **Table 1. Baseline characteristics of included patients**

	<b>Total N=104</b>
Age, median (years)	18.0 (11.8 - 30.0)
Sex, male	71 (68.3)
<b>CL (Treatment) history</b>	
Referred from other health facility	85 (81.7)
Previous CL episode ( <i>n=103</i> )	6 (5.8)
Traditional treatment used	74 (71.1)
Herbal	64 (61.5)
Holy water	12 (11.5)
Burning	1 (0.9)
Other	3 (2.9)
Modern treatment (any)	40 (38.5)
CL-specific treatment	6 (5.8)
<b>Lesion characteristics</b>	
Duration in months, median (IQR)	11.5 (7.0 - 17.0)
Type of lesion	
LCL	30 (28.8)
MCL	69 (66.3)
DCL	5 (4.8)
Nr of active lesions	
1	70 (67.3)
2	16 (15.4)
3	10 (9.6)
≥4	8 (7.7)
Presence of concomitant CL scar	5 (4.8)
Size (largest diam), median IQR ( <i>n=100</i> )	5.0 (4.0 - 8.0)
Location index lesion	
Face	90 (86.5)
Arm/hand	10 (9.6)
Other body part	4 (3.8)
Index lesion presentation	
Plaque	98 (94.2)
Scaly	62 (59.6)
Crusted	55 (52.9)
Papular	54 (51.9)
Erythematous	35 (33.7)
Hyperpigmented	31 (28.9)
Swollen	22 (21.2)
Nodular	21 (20.2)
Ulcerated	18 (17.3)

183 *In case of missing data, the total patients with available data are indicated with (n=x) behind the respective variable*


184

185 *Impact of CL before starting treatment*

186 DLQI data was available for 99 patients before starting treatment, after excluding five invalid

187 questionnaires. Data is shown overall in Figure 2 and separated by the questionnaire used

188 (children when age <15 years and adult for age ≥15) in supplementary Table 1. Overall, the  
189 median DLQI score was 10 (IQR 5-16). Six (6.1%) patients experienced no effect, 26 (26.3%) a  
190 small effect, 22 (22.2%) a moderate effect, 35 (35.4%) a very large effect and ten (10.1%) an  
191 extremely large effect. The domain that was most affected both for children (Supplementary  
192 Table 2) and adults (Supplementary Table 3) was symptoms and feelings (median score 2.0  
193 (1.0 – 3.0 ) for children and 3.0 (2.8 – 4.0) for adults). Adults suffered significantly ( $p < 0.001$ ,  
194 *Mann Whitney test*) more impact due to CL than children, with a median score of 12.5 (IQR  
195 8.0 - 18.0) compared to 7.0 (IQR 3.0 - 11.0).



197 **Figure 2. Dermatological life quality index results by study visit.** *The number of patient in*  
 198 *each of the following categories is shown per study visit: no effect, small effect, moderate*  
 199 *effect, very large effect, extremely large effect. Results for adults and for children aged 4-15*  
 200 *are combined in this figure. Bl: baseline, c1: after cycle 1, c2: after cycle 2, c3: after cycle 3,*  
 201 *d180: after 180 days of starting treatment.*

202 Using patient-reported severity (Table 2), more than half of patients (56, 53.8%) rated their  
 203 lesions as severe before treatment, with another 38 (36.5%) rating their lesion as moderate.

204 **Table 2. Patient-reported severity assessment at the different study visits**

Category	Baseline Total (%) N=104	End of Cycle 1 (%) N=89	End of Cycle 2 (%) N=24	Day 180 N=32 (30.8)
Clear	0 (0)	1 (1.1)	3 (12.5)	11 (34.4)
Almost clear	0 (0)	18 (20.7)	7 (29.2)	8 (25.0)
Mild	9 (8.7)	39 (44.8)	10 (41.7)	5 (15.6)
Moderate	38 (36.5)	28 (32.2)	4 (16.7)	4 (12.5)
Severe	56 (53.8)	1 (1.1)	0 (0)	4 (12.5)
<i>Missing<sup>a</sup></i>	<i>1/104 (1.0)</i>	<i>2/89 (2.2)</i>	<i>1/24<sup>b</sup> (4.2)</i>	<i>4 (11.1)</i>
Median	5.0 (4.0 - 5.0)	3.0 (3.0 - 4.0)	3.0 (2.0 - 3.0)	2.0 (1.0 – 3.3)

205 <sup>a</sup>Missing proportions are calculated taking the total number of patients who came for that visit

206 <sup>b</sup>Patient global assessment was taken from one patient for whom the clinical assessment was missed, but missed from one  
 207 patient who had a clinical outcome

208

209 *Laboratory testing*

210 A skin slit smear test was done to confirm CL in almost all (100, 96.2%) patients but it was  
 211 negative in 56 (56.0%) patients. Although two additional patients were confirmed by fine  
 212 needle aspiration cytology, the majority of patients (58, 55.8%) was treated based on clinical  
 213 diagnosis alone. Although complete blood count (CBC) and organ function tests were  
 214 routinely requested before starting treatment, they were done for only 39 (37.5%) and 24  
 215 (23.1%) of patients at the start of the first treatment cycle. HIV tests were done for a total of  
 216 22 patients (21.2%), and for only one of the five DCL patients; all patients tested were HIV  
 217 negative.

218 During the first cycle of treatment, CBC was done for half of the patients (53, 51.0%). Six  
219 (5.8%) patients had more than one CBC result. Blood count was mostly tested in the middle  
220 of the treatment period. Organ function tests was done in C1 for less than a quarter of  
221 patients (24, 23.1%). ECG was done for only two patients.

### 222 *Treatment and follow-up*

223 A total of 99 patients completed their first treatment cycle of SSG/allopurinol combination  
224 treatment, of which 89 completed all C1 study procedures (Supplementary Figure 1). Most  
225 missed C1 study visits took place during fall 2020, when the hospital was overloaded with  
226 soldiers from the front, and study staff were unable to perform their study activities next to  
227 their routine engagements. Among 88 patients appointed for retreatment at C2, only 37  
228 (42.0%) actually came for a second treatment cycle during the study period (Supplementary  
229 Figure 1). One patient suddenly died in the middle of her second cycle, which could be  
230 potentially related to cardiotoxicity of SSG, but since no ECG was done this cannot be  
231 confirmed. Three patients were discharged before finishing their C2 since the hospital was  
232 evacuated. For nine study patients, procedures for the C2 study visit were missed, mainly due  
233 to the conflict. Only around one third (36/104, 34.6%) of patients came for their D180  
234 outcome assessment.

### 235 *Clinical treatment outcomes*

236 Clinical outcomes are shown in Table 3. Among the 89 patients that completed C1 study  
237 procedures, 4 (4.5%) were cured after 28 days, 71 (79.8%) had substantial improvement, 12  
238 (13.5%) minor improvement, 1 (1.2%) had no improvement, and another 1 (1.2%) worsening.  
239 The majority 83/89 (92.8%) of patients were appointed for another cycle of treatment  
240 (Supplementary Figure 1).

241 After finishing the second treatment cycle, the majority of patients with a known outcome  
 242 (20/24, 83.3%) had substantial improvement, 2 (8.7%) were cured, and 2 (8.7%) had minor  
 243 improvement (Table 3). For the majority of treated patients (21/24, 87.5%), another  
 244 treatment cycle was deemed necessary (Supplementary Figure 1).

245 Half of the patients who came for their D180 visit (18/36, 50.0%) were cured, 11 (30.6%) had  
 246 substantial improvement, 2 (5.6%) minor improvement and 5 (13.9%) worsening. Four study  
 247 patients were continued on treatment after finishing their D180 visit. Outcomes were  
 248 significantly better ( $p=0.032$ ) in the group who came according to the ordered treatment  
 249 extension, with eight of ten with a D180 outcome cured, while this was ten out of 25 (40.0%)  
 250 in those who did not come for planned treatment extension. Still, these ten patients who  
 251 cured, and another ten who had substantial improvement, indicating that further self-healing  
 252 of the lesion can still take place even if further treatment is deemed necessary.

253 **Table 3: Clinical treatment outcomes at the different study visits**

Category	C1 (%)		C2 (%)		C3 (%)	D180 (%)	
	N=89 (85.6)	95% CI	N=24 (23.1)	95% CI	N=4 (3.8)	N=36 (34.6)	95% CI
Cure	4 (4.5)	0 – 13.1	2 (8.3)	0 – 24.7	2 (50.0)	18 (50.0)	36.1 – 68.4
Substantial improvement	71 (79.8)	73.0 – 88.3	20 (83.3)	75.0 – 99.7	2 (50.0)	11 (30.6)	16.7 – 48.9
Minor improvement	12 (13.5)	6.7 – 22.1	2 (8.3)	0 – 24.7		2 (5.6)	0 – 23.9
No improvement	1 (1.1)	0 – 9.7	0 (0)	0 – 16.4		0 (0)	0 – 18.3
Worsening	1 (1.1)	0 – 9.7	0 (0)	0 – 16.4		5 (13.9)	0 – 32.3
Missing <sup>a</sup>	10 (10.1)		9 (27.3)		0	0	

254 <sup>a</sup>Missing are calculated from the total number of patients who completed the treatment cycle. Which was 99 for C1, 33 for  
 255 C2, and 4 for C3.

256  
 257 *Patient-reported outcome data*

258 Patient-reported outcomes are shown in Table 2. After one cycle, patients' rated their lesion  
 259 severity as significantly improved compared to BL ( $p<0.001$ , *Wilcoxon-Signed-Rank test*), with  
 260 a median score of 3.0 (IQR 3.0 – 4.0) compared to 5.0 (IQR 4.0 – 5.0) at BL.

261 At D180, around one third (11/32, 34.4%) of patients reported their lesions to be cleared, one  
 262 quarter (8/32, 25.0%) said they were almost cleared, five (15.6%) said they were mild, four  
 263 (12.5) assessed them to be moderate and four (12.5) as severe. The median score given at  
 264 D180 was significantly lower than at BL ( $p < 0.001$ , *Wilcoxon-Signed-Rank test*).

265 Overall, the proportion of patients cured according to the clinician was significantly different  
 266 from the patient-reported clearance rate (Table 4). Clinician cure rate was higher (13.0 vs 8.3)  
 267 at C2, but lower than patient-reported clearance rate at C1 (4.5 vs 1.1) and D180 (50.0 vs  
 268 34.4) respectively. Agreement measured by Kappa's coefficient between clinical cure and  
 269 patient-reported cure was 0.69 at D180 and 0.78 at C2. At C1, this was much lower, at 0.38.

270 **Table 4. Agreement between clinical and patient-reported outcomes**

	<b>C1</b>	<b>n/N (%)</b>	<b>Clear</b>	<b>Not clear</b>	<b>Kappa-coefficient</b>
271	<b>Cure</b>	4/89 (4.5)	1	3	0.38
272	<b>Not cured</b>	85/89 (95.5)	0	83	
			1/87 (1.1)	86/87 (98.9)	
273	<b>C2</b>		<b>Clear</b>	<b>Not clear</b>	<b>Kappa-coefficient</b>
	<b>Cure</b>	2/24 (8.3)	2	0	0.78
274	<b>Not cured</b>	22/24 (91.7)	1	20	
			3/23 (13.0)	20/23 (87.0)	
275	<b>D180</b>		<b>Clear</b>	<b>Not clear</b>	<b>Kappa-coefficient</b>
	<b>Cure</b>	18/36 (50.0)	11	5	0.69
276	<b>Not cured</b>	18/36 (50.0)	0	16	
			11/32 (34.4)	21/32 (65.6)	

277

278 *Dermatological life quality index after treatment*

279 Results from the DLQI data are shown in Figure 2. Baseline and C1 data was available for 79  
 280 patients, whose median score was 9 (IQR 5-15) at BL and 6 (IQR 3-8) at C1. After treatment,  
 281 the DLQI scores of the 79 patients with BL and C1 data decreased significantly ( $p < 0.001$ ,

282 *Wilcoxon-Signed-Rank-test*), with a median score of 6.0 (IQR 3.0 - 8.0) at the C1 study visit,  
283 compared to 9 (IQR 5-15) at BL. At D180, the median DLQI score of patients was 0 (IQR 0-2),  
284 with 27 (73.0%) patients having no effect, six (16.2%) a small effect, one (2.7%) a moderate  
285 effect, and three (8.1%) a very large effect.

#### 286 *Tracing patient outcomes*

287 Because so few patients came for the outcome assessment visit, we systematically called up  
288 all patients to ask how they perceived their lesion now, and why they did not come for their  
289 D180 visit.

290 We were able to reach three quarters (52/67, 77.6%) of the missed patients by phone. Over  
291 half (29/52, 55.8%) of them reported that their lesion was cured, around a third (17/52,  
292 32.7%) said there was improvement, and four patients (7.7%) reported no change or  
293 worsening. The most common reasons the D180 visit was missed was because of the conflict  
294 (13/52, 25%), because the lesion was deemed to be cured already (12/52, 23.1%), and due to  
295 lack of money or time (10/52, 19.2%). Three patients reported they did not come because  
296 further treatment was not available.

#### 297 *Operational challenges*

298 Many operational challenges were encountered during the study. Drug stockouts occurred  
299 three times: allopurinol was unavailable for about one month in April 2021, SSG stockouts  
300 occurred twice, once for six weeks from late March-2022 until 8 May 2022, and for a second  
301 time from the 12th of August 2022 until the end of the study (over 3.5 months), which also  
302 led to early termination of recruitment.



303 Due to the conflict between the Tigray militants and the national armed forces, the hospital  
304 became one of the main treatment sites for wounded soldiers. As the front advanced further  
305 south, the hospital staff was forced to evacuate on the 14th of October 2021. During the  
306 occupation which lasted several months, the study freezer including all study samples and  
307 camera were stolen, and several documents were lost. Hospital services were restarted from  
308 February 2022 onwards.

309 Another challenge was that the patients requiring treatment exceeded the ward capacity. In  
310 October 2022 there was a list of 171 patients waiting for admission for CL treatment. Of these,  
311 24 were study patients.

## 312 **Discussion**

313 We report on the routine use of systemic SSG in combination with allopurinol in Ethiopia. At  
314 the end of the first treatment cycle, only four patients were considered cured, whereas almost  
315 all other patients were appointed for another treatment cycle. Less than half of appointed  
316 patients returned for further treatment, and only a small number of patients came for their  
317 final outcome assessment visit, where around half of them were cured and around a third  
318 had substantial improvement. According to their own assessment, one third said their lesion  
319 had cleared, but around 70% said their lesion no longer had an impact on their quality of life.  
320 In addition, this study highlights the effects of the conflict in Northern Ethiopia on treatment  
321 provision for CL, but also shows that drug stockouts and shortage of beds - problems not  
322 directly related to the conflict- impact treatment.

323 Most patients had insurance [14] which covered the cost of treatment, and since patients  
324 need to be referred in order to qualify for health insurance to cover hospital costs, the  
325 majority was referred from other health facilities. However, the fact that most patients still

326 came with longstanding lesions after trying traditional treatment and various other modern  
327 treatments, highlights delays in seeking care. This likely contributes to larger lesion size and  
328 more severe scar formation, thereby aggravating the psychosocial impact of CL.

329 In this patient population getting systemic treatment, the impact of CL on their quality of life  
330 prior to treatment was high, with 35% of patients indicating a very large, and 10% an  
331 extremely large impact. More than half of the patients rated their lesion as severe before  
332 treatment. This clearly shows the big impact CL has on these patients, and emphasizes the  
333 need for treatment and psychosocial support. Although clinical cure rates at the final visit  
334 were relatively poor around 50%, an additional 30% had substantial improvement and  
335 patient-reported outcomes at this time indicated a significant improvement in their quality of  
336 life as well as their severity rating of their lesion. Although social desirability bias may play a  
337 role, our findings seem to highlight that even though the proportion of patients cured is low,  
338 most patients experience a significant improvement in their lesion appearance and associated  
339 quality of life. Therefore, treatment still seems to have a positive impact on patients.

340 In this setting, systemic SSG 20mg per kg with a maximum of 850mg/day is routinely used  
341 with low dose allopurinol of 100mg per day, without a clear evidence-base. Evidence on the  
342 use of allopurinol for treatment of CL is generally conflicting. Clinical trials in Iran [15] and  
343 Colombia [16],[17] showed that allopurinol significantly increased the effectiveness of  
344 antimonials, and that this combination can cure lesions that failed to respond to other  
345 treatments [18]–[20]. On the other hand, randomized clinical trials in Peru [21] and Iran [22]  
346 showed no added benefit of allopurinol compared to antimonials alone. However, almost all  
347 previous studies used allopurinol at a high dose of 20mg/kg, adding up to a daily dose usually  
348 exceeding 1000mg- in stark contrast with our study where patients received a daily

349 allopurinol dose of only 100mg. This low-dose was started based on expert opinion without  
350 proper evidence, and has been continued since only at this center, further underlining the  
351 need for clear evidence-based treatment guidelines.

352 Due to the low number of patients with final treatment outcomes, we should be careful to  
353 draw conclusions about effectiveness of SSG/low-dose allopurinol. Poor follow-up data is  
354 partially caused by the conflict, but also related to treatment outcomes, as both patients with  
355 very poor outcomes and those already cured are unlikely to come to follow-up. However,  
356 informal outcome data collected by calling patients indicates that in patients who missed their  
357 outcome visit, the proportions cured and improved were similar to those who attended their  
358 outcome visit. Cure rates are similar to what our group reported for 28 days of miltefosine  
359 treatment [23]. Since the majority of the cured patients in this study were hospitalized for at  
360 least two treatment cycles of SSG with allopurinol, miltefosine seems preferable, as patients  
361 took their treatment at home after one week of hospitalization.

362 The decision to extend treatment was very common, although many patients never actually  
363 returned for further treatment. It is hard to draw conclusions on the outcomes of treatment  
364 extension, as the lesion severity and response to the first treatment cycle is likely related to  
365 patients coming for follow-up. Since more than half of the patients who did not come for their  
366 appointed treatment extension were still cured at D180, treatment extension does not always  
367 seem needed. However, at Boru Meda hospital, due to fear of relapse, treatment is typically  
368 extended if the lesion is not cured, which is assessed directly or two weeks after completing  
369 the first treatment cycle. Some argue that this is too early, as tissue repair is thought to still  
370 take several weeks after parasites have been killed [24]. Formal randomized studies are

371 needed to assess the additive effect of treatment extension, but consensus on when and for  
372 whom treatment extension is needed could also provide more clarity.

373 Our study highlights several important operational challenges of treating CL in Ethiopia. Drug  
374 stockouts were frequently seen, indicating that drug supplies are not consistently reliable.  
375 SSG is mainly supplied by WHO through the Ministry of Health, but it seems the supply does  
376 not match the current needs of CL treatment centers. Although anti-leishmanial drugs are  
377 listed in the essential drug list of the country[25], consistent supply should be ensured. The  
378 impact of war on CL treatment was large, as hospital services were shut down for months,  
379 treatments were interrupted, and follow-up was perturbed. Unavailability of drugs and  
380 interruption of services probably contributed to the long waiting list for inpatient treatment.  
381 Insufficient treatment capacity further interferes with treatment schedules and follow-up, as  
382 most patients who were reappointed for treatment did not come, or could not be treated due  
383 to lack of space. Ambulatory treatment with oral miltefosine as an oral drug could solve part  
384 of the problem, although cost and access are issues that currently limit widespread  
385 implementation.

386 A recent study in Ethiopia highlighted that there is severe underreporting of CL, and that the  
387 majority of patients never seek care at modern treatment facilities [26]. According to the  
388 2030 Neglected Tropical Disease (NTD) roadmap [27], 85% of all CL cases should be detected  
389 and 95% of them should be treated, which would increase patient flow to treatment centers.  
390 The long waitlist for inpatient treatment indicates treatment facilities may not have the  
391 capacity needed to treat the CL caseload and meet the roadmap targets. To succeed, there  
392 should either be a great scale-up of referral treatment sites if inpatient treatment with  
393 systemic antimonials be continued. Boru Meda has recently upgraded their dermatological

394 treatment capacity with 16 beds, but waiting lists for treatment persist. Rather, innovative  
395 approaches such as decentralization should be explored to meet increasing demands of CL  
396 diagnosis and care. These could follow the multi-drug resistant tuberculosis system, where  
397 patients are diagnosed at the referral center, but take treatment at lower level health facilities  
398 closed to their home [28].

399 Although the guidelines advise parasitological confirmation of patients before treatment, in  
400 practice many patients are treated empirically. Data from a previous study in a similar  
401 population showed that this approach seems sound, as 34/40 (85%) of microscopy negative  
402 patients were confirmed by PCR [23]. Unfortunately, we could not confirm the diagnosis by  
403 PCR in this study as samples were lost during the hospital's occupation. Other lab tests were  
404 not routinely performed, and ECG was rarely done. There was one patient who died during  
405 the second treatment cycle. Since SSG is known to cause QTc interval prolongation, [29], we  
406 cannot exclude the death was due to SSG-related QTc prolongation or arrhythmias which  
407 could have been identified on ECG. This case emphasizes the need of ECG monitoring at least  
408 before the start of treatment. Cheap and portable six-lead ECG devices attached to mobile  
409 phones were recently FDA approved for measuring QTc intervals [30], and could facilitate  
410 clearance for treatment with SSG at the health center or primary hospital.

411 This study had several limitations. Since photographs were lost due to the stolen camera, it  
412 was impossible to systematically obtain a second opinion for outcome assessment of patients.  
413 Therefore, outcome assessment is solely based on the opinion of the treating clinician, which  
414 is subjective, although this reflects what is routinely done. In future studies, we suggest  
415 outcome assessment be done by two independent dermatologists, preferably in person so  
416 flattening can be addressed properly by palpation. Second, final outcome data could be

417 obtained for only a small number of patients, which affects the validity of our outcome data.  
418 Although lost-to-follow-up for final outcomes was very high, most patients could be reached  
419 by phone. As patient-reported outcomes were correlated with clinical outcomes, this seems  
420 an opportunity to supplement outcome data for future studies investigating treatment  
421 effectiveness.

## 422 **Conclusions**

423 Treatment with SSG and low-dose allopurinol led to low cure rates after one cycle, with  
424 frequent treatment extension. After 180 days, around 50% of patients had clinical cure and  
425 30% improvement, while patient-reported outcomes significantly improved. Treatment  
426 stockouts were frequent, and bed capacity was limited leading to long waiting lists for  
427 treatment. Increasing treatment capacity or decentralization to lower level health facilities  
428 seem vital to meet the WHO NTD roadmap goals aimed to improve access to diagnosis and  
429 treatment for cutaneous leishmaniasis in Ethiopia.

430

431 **Author contributions**

432 Conceptualization: SvH, JvG, SGA; Methodology, SvH, JvG, SGA; Formal Analysis: SvH;  
433 Investigation: FB, SH, FT; Resources: JvG; Data Curation: FB, SH, FT; Writing – Original Draft  
434 Preparation: SvH; Writing – Review & Editing: JvG, SGA; Visualization: SvH; Supervision: SvH,  
435 SGA; Project Administration: SvH, SGA, FT; Funding Acquisition, JvG.

436 **Funding**

437 This work was supported by the Directorate-General Development cooperation and  
438 Humanitarian Aid (DGD), under the FA4 framework collaboration of the Institute of Tropical  
439 Medicine (Antwerp, Belgium) and the University of Gondar (Gondar, Ethiopia), of which Boru  
440 Meda was funded as a satellite site. The funders had no role in the study design, data  
441 collection and analysis, decision to publish, or preparation of the manuscript.

442 **Institutional Review Board Statement**

443 The study was conducted according to the guidelines of the Declaration of Helsinki, and  
444 approved by the ethical review committees of the Institute of Tropical Medicine, Antwerp  
445 (Ref 1351/20, 23 March 2020); the University hospital of Antwerp (Ref 20/15/183, 27 April  
446 2020), and Wollo University College of Medicine and Health Sciences Ethics committee,  
447 Dessie (Ref 127/02/13, 14 October 2020).

448 **Informed consent statement**

449 Informed consent was obtained from subjects involved in the study, or from the guardian if  
450 patients were below 12 years old. Assent was additionally obtained from children aged 12-  
451 17. Patients specifically consented to having their photograph taken and for it to be shared -  
452 granted they could not be identified -, and for patient tracing by phone. The study was  
453 registered at ClinicalTrials.gov as NCT04699383.

454 **Data availability statement**

455 Data will not be made openly accessible due to ethical and privacy concerns. Data can  
456 however be made available after approval of a motivated and written request to ITMs  
457 Research Data Access Committee ([ITMresearchdataaccess@itg.be](mailto:ITMresearchdataaccess@itg.be)).

#### 458 **Acknowledgements**

459 We want to thank the patients who agreed to participate in this study, and all the Boru Meda  
460 staff who were involved in data collection and processing. We would also like to thank  
461 University of Gondar staff Mezgebu Silamsaw and Tarekegn Asmamaw and ITM staff Myrthe  
462 Pareyn and Gudrun van Belle who helped with project administration and financing.

#### 463 **Conflicts of Interest**

464 The authors declare no conflict of interest.

465

466



467 **References**

- 468 [1] Alvar, J.; Vélez, I. D.; Bern, C.; Herrero, M.; Desjeux, P.; Cano, J.; Jannin, J.; den Boer,  
469 M.; WHO Leishmaniasis Control Team. Leishmaniasis Worldwide and Global Estimates  
470 of Its Incidence. *PLoS One* **2012**, 7 (5), e35671.  
471 <https://doi.org/10.1371/journal.pone.0035671>.
- 472 [2] van Henten, S.; Adriaensen, W.; Fikre, H.; Akuffo, H.; Diro, E.; Hailu, A.; Van der  
473 Auwera, G.; van Griensven, J. Cutaneous Leishmaniasis Due to *Leishmania Aethiopica*.  
474 *EClinicalMedicine* **2018**, 6, 69–81. <https://doi.org/10.1016/J.ECLINM.2018.12.009>.
- 475 [3] *Guideline for Diagnosis, Treatment & Prevention of Leishmaniasis in Ethiopia*; 2013.
- 476 [4] Fikre, H.; Mohammed, R.; Atinafu, S.; van Griensven, J.; Diro, E. Clinical Features and  
477 Treatment Response of Cutaneous Leishmaniasis in North-West Ethiopia. *Trop. Med.*  
478 *Int. Heal.* **2017**, 22 (10), 1293–1301. <https://doi.org/10.1111/tmi.12928>.
- 479 [5] Tesfa, D.; Manaye, N.; De Vries, H. J.; Van Griensven, J.; Enbiale, W. Clinical Pattern  
480 and Treatment Outcome of Cutaneous Leishmaniasis in Two Hospitals in Bahir Dar,  
481 Ethiopia (2017-2021). *J. Infect. Dev. Ctries.* **2022**, 16 (08.1), 26S-34S.  
482 <https://doi.org/10.3855/jidc.15979>.
- 483 [6] Seife, T.; Benecha, A. K.; Zewdu, F. T.; Ayal, A.; Misganaw, M. Treatment Patterns and  
484 Effectiveness of Anti-Leishmaniasis Agents for Patients with Cutaneous Leishmaniasis  
485 at Boru Meda Hospital, South Wollo, North East Ethiopia, 2017/18. *J. Clin. Exp.*  
486 *Dermatol. Res.* **2018**, 09 (03). <https://doi.org/10.4172/2155-9554.1000450>.
- 487 [7] van Griensven, J.; Gadisa, E.; Aseffa, A.; Hailu, A.; Beshah, A. M.; Diro, E. Treatment of  
488 Cutaneous Leishmaniasis Caused by *Leishmania Aethiopica*: A Systematic Review.

- 489 *PLoS Negl. Trop. Dis.* **2016**, *10* (3), e0004495.
- 490 <https://doi.org/10.1371/journal.pntd.0004495>.
- 491 [8] Erber, A. C.; Arana, B.; Bennis, I.; Ben Salah, A.; Boukthir, A.; Castro Noriega, M. D. M.;  
492 Cissé, M.; Cota, G. F.; Handjani, F.; Kebede, M. G.; Lang, T.; López Carvajal, L.; Marsh,  
493 K.; Martinez Medina, D.; Plugge, E.; Olliaro, P. An International Qualitative Study  
494 Exploring Patients' Experiences of Cutaneous Leishmaniasis: Study Set-up and  
495 Protocol. *BMJ Open* **2018**, *8* (6), e021372. [https://doi.org/10.1136/bmjopen-2017-](https://doi.org/10.1136/bmjopen-2017-021372)  
496 [021372](https://doi.org/10.1136/bmjopen-2017-021372).
- 497 [9] Abdela, S. G.; Diro, E.; Zewdu, F. T.; Berhe, F. T.; Yeshaneh, W. E.; Tamirat, K. S.;  
498 Tweya, H.; Timire, C.; van Griensven, J. Looking for NTDs in the Skin; an Entry Door for  
499 Offering Patient Centered Holistic Care. *J. Infect. Dev. Ctries.* **2020**, *14* (6.1), 16S-21S.  
500 <https://doi.org/10.3855/jidc.11707>.
- 501 [10] Finlay, A. Y.; Khan, G. K. Dermatology Life Quality Index (DLQI)—a Simple Practical  
502 Measure for Routine Clinical Use. *Clin. Exp. Dermatol.* **1994**, *19* (3), 210–216.  
503 <https://doi.org/10.1111/j.1365-2230.1994.tb01167.x>.
- 504 [11] Finlay, A. Y.; Sampogna, F. What Do Scores Mean? Informed Interpretation and  
505 Clinical Judgement Are Needed. *Br. J. Dermatol.* **2018**, *179* (5), 1021–1022.  
506 <https://doi.org/10.1111/BJD.17028>.
- 507 [12] Harris, P. A.; Taylor, R.; Thielke, R.; Payne, J.; Gonzalez, N.; Conde, J. G. Research  
508 Electronic Data Capture (REDCap)—A Metadata-Driven Methodology and Workflow  
509 Process for Providing Translational Research Informatics Support. *J. Biomed. Inform.*  
510 **2009**, *42* (2), 377–381. <https://doi.org/10.1016/J.JBI.2008.08.010>.

- 511 [13] Team R Core. R: A Language and Environment for Statistical Computing. *R Foundation*  
512 *for Statistical Computing, Vienna, Austria*. 2023. <https://www.r-project.org>.
- 513 [14] Ministry of Health. *Ethiopian Health Insurance*. Ministry of Health Ethiopia.  
514 [https://www.moh.gov.et/site/Ethiopian\\_Health\\_Insurance](https://www.moh.gov.et/site/Ethiopian_Health_Insurance).
- 515 [15] Esfandiarpour, I.; Alavi, A. Evaluating the Efficacy of Allopurinol and Meglumine  
516 Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis. *Int. J.*  
517 *Dermatol.* **2002**, *41* (8), 521–524.
- 518 [16] Martinez, S.; Marr, J. J. Allopurinol in the Treatment of American Cutaneous  
519 Leishmaniasis. *N. Engl. J. Med.* **1992**, *326* (11), 741–744.  
520 <https://doi.org/10.1056/NEJM199203123261105>.
- 521 [17] Martinez, S.; Gonzalez, M.; Vernaza, M. E. Treatment of Cutaneous Leishmaniasis  
522 with Allopurinol and Stibogluconate. *Clin. Infect. Dis.* **1997**, *24* (2), 165–169.
- 523 [18] Baum, K. F.; Berens, R. L. Successful Treatment of Cutaneous Leishmaniasis with  
524 Allopurinol After Failure of Treatment with Ketoconazole. *Clin. Infect. Dis.* **1994**, *18*  
525 (5), 813–815. <https://doi.org/10.1093/clinids/18.5.813>.
- 526 [19] Momeni, A. Z.; Aminjavaheri, M. Successful Treatment of Non-Healing Cases of  
527 Cutaneous Leishmaniasis, Using a Combination of Meglumine Antimoniate plus  
528 Allopurinol. *Eur. J. dermatology EJD2* **2003**, *13* (1), 40–43.
- 529 [20] Esfandiarpour, I.; Dabiri, S. H. Treatment of Cutaneous Leishmaniasis Recidivans with  
530 a Combination of Allopurinol and Meglumine Antimoniate: A Clinical and Histologic  
531 Study. *Int. J. Dermatol.* **2007**, *46* (8), 848–852. [https://doi.org/10.1111/j.1365-](https://doi.org/10.1111/j.1365-4632.2007.03086.x)  
532 [4632.2007.03086.x](https://doi.org/10.1111/j.1365-4632.2007.03086.x).

- 533 [21] Llanos–Cuentas, A.; Echevarria, J.; Cruz, M.; La Rosa, A.; Campos, P.; Campos, M.;  
534 Franke, E.; Berman, J.; Modabber, F.; Marr, J. Efficacy of Sodium Stibogluconate Alone  
535 and in Combination with Allopurinol for Treatment of Mucocutaneous Leishmaniasis.  
536 *Clin. Infect. Dis.* **1997**, *25* (3), 677–684. <https://doi.org/10.1086/513776>.
- 537 [22] Momeni, A. Z.; Reiszadae, M. R.; Aminjavaheri, M. Treatment of Cutaneous  
538 Leishmaniasis with a Combination of Allopurinol and Low-Dose Meglumine  
539 Antimoniate. *Int. J. Dermatol.* **2002**, *41* (7), 441–443. [https://doi.org/10.1046/J.1365-](https://doi.org/10.1046/J.1365-4362.2002.01527.X)  
540 [4362.2002.01527.X](https://doi.org/10.1046/J.1365-4362.2002.01527.X).
- 541 [23] van Henten, S.; Tesfaye, A. B.; Abdela, S. G.; Tilahun, F.; Fikre, H.; Buyze, J.; Kassa, M.;  
542 Cnops, L.; Pareyn, M.; Mohammed, R.; Vogt, F.; Diro, E.; van Griensven, J. Miltefosine  
543 for the Treatment of Cutaneous Leishmaniasis—A Pilot Study from Ethiopia. *PLoS*  
544 *Negl. Trop. Dis.* **2021**, *15* (5), e0009460.  
545 <https://doi.org/10.1371/journal.pntd.0009460>.
- 546 [24] Olliaro, P.; Vaillant, M.; Arana, B.; Grogl, M.; Modabber, F.; Magill, A.; Lapujade, O.;  
547 Buffet, P.; Alvar, J. Methodology of Clinical Trials Aimed at Assessing Interventions for  
548 Cutaneous Leishmaniasis. *PLoS Negl. Trop. Dis.* **2013**, *7* (3), e2130.  
549 <https://doi.org/10.1371/journal.pntd.0002130>.
- 550 [25] Ethiopian Food and drug authority and Ministry of health. *Ethiopian Essential*  
551 *Medicines List Sixth Edition*; 2020.
- 552 [26] Merdekios, B.; Pareyn, M.; Tadesse, D.; Getu, S.; Admassu, B.; Girma, N.; Leirs, H.; van  
553 Geertruyden, J. P.; van Griensven, J. Detection of Cutaneous Leishmaniasis Foci in  
554 South Ethiopia. *Am. J. Trop. Med. Hyg.* **2021**, *105* (1), 156–158.

555 <https://doi.org/10.4269/AJTMH.20-0708>.

556 [27] World Health Organization. *Ending the Neglect to Attain the Sustainable Development*  
557 *Goals: A Road Map for Neglected Tropical Diseases 2021–2030*; 2020.

558 <https://www.who.int/publications/i/item/9789240010352> (accessed 2021-10-25).

559 [28] Federal Democratic Republic of Ethiopia Ministry of Health. *National Strategic Plan*  
560 *Tuberculosis and Leprosy Control 2013-2020.*; 2017; Vol. 13.

561 [29] Oliveira, L. F.; Schubach, A. O.; Martins, M. M.; Passos, S. L.; Oliveira, R. V.; Marzochi,  
562 M. C.; Andrade, C. A. Systematic Review of the Adverse Effects of Cutaneous  
563 Leishmaniasis Treatment in the New World. *Acta Trop.* **2011**, *118* (2), 87–96.

564 <https://doi.org/10.1016/J.ACTATROPICA.2011.02.007>.

565 [30] ALIVECOR. *FDA Clears Personal ECG Device for Measurement of QTc Interval, a Critical*  
566 *Marker for Patient Safety.* [https://www.alivecor.com/press/press\\_release/fda-clears-](https://www.alivecor.com/press/press_release/fda-clears-personal-ecg-device-for-measurement-of-qtc-interval/#)  
567 [personal-ecg-device-for-measurement-of-qtc-interval/#](https://www.alivecor.com/press/press_release/fda-clears-personal-ecg-device-for-measurement-of-qtc-interval/#) (accessed 2023-04-13).

568

569